India's drug price regulator has set a cap on the prices of 18 new drugs for treatment of diabetes, hypertension, and pneumonia from Diwali. The Drugs Price Control Order fixes MRP of these drugs at the average of those available in the particular segment. Companies need to get permission six months in advance if they want to discontinue the drug. 